[CAS NO. 1135-24-6] Ferulic acid
PRODUCTS SPECIFICATIONS [1135-24-6]
DESCRIPTION [1135-24-6]
Overview
| MDL | MFCD00004400 |
|---|---|
| Molecular Weight | 194.18 |
| Molecular Formula | C10H10O4 |
| SMILES | O=C(O)/C=C/C1=CC=C(O)C(OC)=C1 |
3 Publications Citing Use of MCE
Summary
Ferulic acid is a novel fibroblast growth factor receptor 1 ( FGFR1 ) inhibitor with IC 50 s of 3.78 and 12.5 μM for FGFR1 and FGFR2 , respectively.
IC50 & Target
|
FGFR1 3.78 μM (IC 50 ) |
FGFR2 12.5 μM (IC 50 ) |
Human Endogenous Metabolite
|
In Vitro
Ferulic acid (FA) is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC 50 s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively. Ferulic acid exhibits great inhibitory activity on FGFR1 with an inhibitory rate of 92% at 1 µM. The proliferation of HUVEC stimulated by FGF1 is markedly decreased after Ferulic acid treatment ranging from 5 to 40 μM for 24 h. Ferulic acid does not exert significant cell viability up to 20 μM, but over 30 μM Ferulic acid exhibits a cytotoxic effect in HUVEC compare to the control. Ferulic acid inhibits FGF1-induced HUVEC migration and invasion in a dose-dependent manner. Ferulic acid markedly suppresses the FGF1-induced phosphorylation of PI3K and Akt. Ferulic acid treatments significantly inhibit MMP-2 and MMP-9 expression stimulated by FGF1 [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Treatment with Ferulic acid (FA) potently inhibits FGF1-induced neovascularization. It is found that intragastric administration of Ferulic acid markedly inhibits tumor volume and tumor weight, as compare to the counterparts treated with DMSO. Furthermore, Ferulic acid treatment is well tolerated, and there is no significant difference in weight between the vehicle group and the FA-treated groups [1] . Ferulic acid (0.01, 0.1, 1 or 10 mg/kg) given by oral route decreases significantly the immobility time in the forced swimming test (FST) and tail suspension test (TST), whereas produces no effect in the open-field test. Results demonstrate that the administration of Ferulic acid (0.001 mg/kg, p.o.) boosts the antidepressant-like effect of fluoxetine (5 mg/kg, p.o.) in the TST [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00777543 | Maastricht University Medical Center |
Healthy Males
|
November 2008 | Not Applicable |
Appearance
Solid
Source
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 514.99 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.1499 mL | 25.7493 mL | 51.4986 mL |
| 5 mM | 1.0300 mL | 5.1499 mL | 10.2997 mL |
| 10 mM | 0.5150 mL | 2.5749 mL | 5.1499 mL |
References
- [1] Yang GW, et al. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis. Int J Mol Sci. 2015 Oct 12;16(10):24011-31.
- [2] Zeni AL, et al. Ferulic acid exerts antidepressant-like effect in the tail suspension test in mice: evidence for the involvement of the serotonergic system. Eur J Pharmacol. 2012 Mar 15;679(1-3):68-74.
Synonyms